BioCentury
ARTICLE | Clinical News

Actimmune interferon gamma-1b regulatory update

April 20, 2015 7:00 AM UTC

FDA granted Fast Track designation to Horizon’s Actimmune interferon gamma-1b to treat Friedreich’s ataxia. This quarter, Horizon plans to start a Phase III trial of Actimmune in the indication, for w...